Mapping the long slow progression of neurodegeneration leading to Alzheimer’s disease
暂无分享,去创建一个
[1] Jerry L. Prince,et al. A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.
[2] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[3] B. Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.
[4] Janet S. Reddin,et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease , 2011, Neurology.
[5] L. McEvoy,et al. Predicting MCI outcome with clinically available MRI and CSF biomarkers , 2011, Neurology.
[6] T. Goldberg,et al. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. , 2011, Archives of general psychiatry.
[7] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[8] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[9] A. Dale,et al. Global clinical dementia rating of 0.5 in MCI masks variability related to level of function , 2011, Neurology.
[10] Nick C. Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup , 2011 .
[11] Cindee M. Madison,et al. Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.
[12] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[13] J. Detre,et al. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.
[14] Richard L. Doty,et al. Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease , 2008, Biological Psychiatry.
[15] David C. Alsop,et al. Hippocampal hyperperfusion in Alzheimer's disease , 2008, NeuroImage.
[16] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[17] E. Twamley,et al. Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease , 2006, Journal of the International Neuropsychological Society.
[18] Keith A. Johnson,et al. P2-366 Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees , 2006, Alzheimer's & Dementia.
[19] Lars Bäckman,et al. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. , 2005, Neuropsychology.
[20] Alex Kiss,et al. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years , 2005, Neurology.
[21] C. Iadecola. Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[22] L. Thal,et al. Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals , 2002, Neurology.
[23] L. Thal,et al. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. , 1999, Psychology and aging.
[24] Vijaya L. Melnick,et al. Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.
[25] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.